Canaccord downgraded Bioceres (BIOX) to Hold from Buy with a price target of $2.50, down from $6.50. The company’s sales and adjusted EBITDA loss in fiscal Q4 were lower than expected due to macro challenges being faced by agriculture customers in in its core market of Argentina, the analyst tells investors in a research note. The firm cites the challenging market in Argentina and the overhang of Bioceres’ parent company reducing its position for the downgrade.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX:
- Bioceres Crop Solutions Faces Challenging Fiscal Year
- Bioceres Crop Solutions Earnings Call Highlights Challenges and Recovery
- Bioceres Crop Solutions Faces Challenging FY25 Amid Argentine Market Pressures
- Bioceres reports Q4 revenue $74.7M, consensus $110.08M
- BIOX Upcoming Earnings Report: What to Expect?